Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06097975 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

Study acronym: NEO-GLITIPNI
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Jun 1, 2025 → Jun 1, 2027
See other at-risk trials from Universitair Ziekenhuis Brussel

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 1, 2025 to Jun 1, 2027 Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Dec 1, 2025 to Dec 1, 2027
    • Eligibility criteria expanded, about 12 words
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2024 to Mar 15, 2024
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this phase I interventional study is to determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable reccurent glioblastoma. Participants will: * receive neo-adjuvant administration of intravenous immunotherapy * followed by a maximal safe neurosurgical resection * afterwards, immunotherapy will be injected into the brain tissue * followed by insertion of an Ommaya reservoir * postoperatively, administration of immunotherapy will be continued
Trial Details
NCT Number NCT06097975
Lead Sponsor Universitair Ziekenhuis Brussel
Conditions
(from sponsor)		 Recurrent Glioblastoma
Related terms Glioblastoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov